DART Study A phase 2 randomized trial of dalantercept plus axitinib versus placebo plus axitinib in advanced renal cell carcinoma (RCC): Results from the part 2 placebo-controlled trial - 100098

Spotlight
Video

DART Study A phase 2 randomized trial of dalantercept plus axitinib versus placebo plus axitinib in advanced renal cell carcinoma (RCC): Results from the part 2 placebo-controlled trial

kidneycancer has 473 videos Subscribe Here

Loading........
Description: Martin H. Voss, MD of Memorial Sloan Kettering outlines the DART Study: A phase 2 randomized trial of dalantercept plus axitinib versus placebo plus axitinib in advanced renal cell carcinoma (RCC): Results from the part 2 placebo-controlled trial at the 2017 Kidney Cancer Association symposium in Miami, FL.
Shared By : kidneycancer
Posted on : 11/07/17
Added : 10 months ago
Category : Kidney Cancer



Recommended

Nothing found.